These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24370686)

  • 1. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis.
    Xu CP; Xue XJ; Liang N; Xu DG; Liu FJ; Yu XS; Zhang JD
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):549-59. PubMed ID: 24370686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer.
    Kim DW; Lee G; Hong TS; Li G; Horick NK; Roeland E; Keane FK; Eyler C; Drapek LC; Ryan DP; Allen JN; Berger D; Parikh AR; Mullen JT; Klempner SJ; Clark JW; Wo JY
    Ann Surg Oncol; 2022 Jan; 29(1):242-252. PubMed ID: 34480285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
    Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
    Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
    Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
    World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.
    He J; Lv N; Yang Z; Luo Y; Zhong W; Wu C
    Int J Surg; 2024 Jun; 110(6):3900-3909. PubMed ID: 38935819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
    Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
    Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
    Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
    PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer.
    Kranzfelder M; Schuster T; Geinitz H; Friess H; Büchler P
    Br J Surg; 2011 Jun; 98(6):768-83. PubMed ID: 21462364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients.
    Yuan M; Bao Y; Ma Z; Men Y; Wang Y; Hui Z
    Front Oncol; 2021; 11():628706. PubMed ID: 33777777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
    Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
    [No Abstract]   [Full Text] [Related]  

  • 14. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies.
    Tomasello G; Ghidini M; Ghidini A; Trevisan F; Celotti A; Russo A; Gambini D; Indini A; Rijavec E; Bareggi C; Galassi B; Petrelli F
    Radiother Oncol; 2021 Nov; 164():13-19. PubMed ID: 34509562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
    Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
    Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review.
    Liu W; Fu XL; Yang JY; Liu DJ; Li J; Zhang JF; Huo YM; Yang MW; Hua R; Sun YW
    Medicine (Baltimore); 2016 Apr; 95(15):e3009. PubMed ID: 27082545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.
    Shaikh I; Askari A; Ourû S; Warusavitarne J; Athanasiou T; Faiz O
    Int J Colorectal Dis; 2015 Jan; 30(1):19-29. PubMed ID: 25367179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis.
    Yin S; Wang P; Xu X; Tan Y; Huang J; Xu H
    J Cancer; 2019; 10(14):3094-3101. PubMed ID: 31289579
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.
    Lu H; Sun Y; Zhu Z; Yao J; Xu H; Huang R; Huang B
    Ann Surg Oncol; 2022 Oct; 29(11):6962-6975. PubMed ID: 35723792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.